English Polski
Vol 18, No 3 (2021)
Review paper
Published online: 2021-05-05
Page views 1134
Article views/downloads 405
Get Citation

Connect on Social Media

Connect on Social Media

The impact of the COVID-19 pandemic on the schizophrenia - a literature review

Patrycja Pabis1, Joanna Agnieszka Smolarczyk-Kosowska2, Magdalena Piegza2
Psychiatria 2021;18(3):212-220.


This paper provides an overview of the impact the SARS-CoV-2 pandemic had on the schizophrenics and the
course of their disease. We presented the factors increasing the risk of infection and mortality in these patients.
We then focused on the means to reduce the risk of the relapse of schizophrenia, as well as on the assessment
of stress level perceived in the study group. Furthermore, we analyzed the work-flow and organization of work
in the institutionalized support facilities for patients suffering from schizophrenia. Additionally, we examined
the pros and cons of using atypical drugs, clozapine in particular, in the schizophrenia treatment, and discussed
the issue of telemedicine and long-distance medical advice, which proved vital in the times of the pandemic.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?


  1. Skorupska A, Czyżkowicz K. Deficyty funkcjonowania społecznego w schizofrenii – przegląd literatury. Fam Med Prim Care Rev. 2007; 4: 1060S–1063S.
  2. Kozloff N, Mulsant BH, Stergiopoulos V, et al. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophr Bull. 2020; 46(4): 752–757.
  3. Padala SP, Dennis RA, Caceda R. Why COVID-19 Is Especially Difficult for Those With Schizophrenia: Reasons and Solutions. Prim Care Companion CNS Disord. 2020; 22(5).
  4. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021; 20(1): 124–130.
  5. Fonseca L, Diniz E, Mendonça G, et al. Schizophrenia and COVID-19: risks and recommendations. Braz J Psychiatry. 2020; 42(3): 236–238.
  6. Shinn AK, Viron M. Perspectives on the COVID-19 Pandemic and Individuals With Serious Mental Illness. J Clin Psychiatry. 2020; 81(3).
  7. Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry. 2005; 162(2): 370–376.
  8. Fond G, Pauly V, Leone M, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. Encephale. 2021; 47(2): 89–95.
  9. Fond G, Pauly V, Leone M, et al. Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study. Schizophr Bull. 2021; 47(3): 624–634.
  10. Cereda E, Bogliolo L, de Stefano L, et al. A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019. Curr Opin Clin Nutr Metab Care. 2021; 24(1): 102–107.
  11. Hulsbosch AM, Nugter MA, Tamis P, et al. Videoconferencing in a mental health service in The Netherlands: A randomized controlled trial on patient satisfaction and clinical outcomes for outpatients with severe mental illness. J Telemed Telecare. 2017; 23(5): 513–520.
  12. Melamed OC, Hahn MK, Agarwal SM, et al. Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies. Gen Hosp Psychiatry. 2020; 66: 30–33.
  13. Miu A, Vo H, Palka J, et al. Teletherapy with serious mental illness populations during COVID-19: telehealth conversion and engagement. Counselling Psychology Quarterly. 2020: 1–18.
  14. Maguire PA, Looi JCl. COVID-19 telehealth challenges for patients with schizophrenia and other psychoses. Aust N Z J Psychiatry. 2020 [Epub ahead of print]: 4867420968887.
  15. Krzystanek M, Borkowski M, Skałacka K, et al. A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. Schizophr Res. 2019; 204: 389–396.
  16. Kopelovich SL, Monroe-DeVita M, Buck BE, et al. Community Mental Health Care Delivery During the COVID-19 Pandemic: Practical Strategies for Improving Care for People with Serious Mental Illness. Community Ment Health J. 2021; 57(3): 405–415.
  17. Thomas RK, Suleman R, Mackay M, et al. Adapting to the impact of COVID-19 on mental health: an international perspective. J Psychiatry Neurosci. 2020; 45(4): 229–233.
  18. Krzystanek M, Stolarczyk A, Borkowski M, et al. et al.. Telemedyczna terapia poznawczo-behawioralna Psychiatria. 2018; 15(2): 110–116.
  19. De Leon J, Sanz EJ, De Las Cuevas C. Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions. Schizophr Bull. 2020; 46(1): 1–3.
  20. Hamada K, Fan X. The impact of COVID-19 on individuals living with serious mental illness. Schizophr Res. 2020; 222: 3–5.
  21. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020 [Epub ahead of print]; 45(4): 200061–223.
  22. Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge. Schizophr Res. 2020; 220: 265–266.
  23. González-Blanco L, Dal Santo F, García-Álvarez L, et al. COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls? Schizophr Res. 2020; 223: 192–198.
  24. Michalska da Rocha B, Rhodes S, Vasilopoulou E, et al. Loneliness in Psychosis: A Meta-analytical Review. Schizophr Bull. 2018; 44(1): 114–125.
  25. Pinkham AE, Ackerman RA, Depp CA, et al. A Longitudinal Investigation of the Effects of the COVID-19 Pandemic on the Mental Health of Individuals with Pre-existing Severe Mental Illnesses. Psychiatry Res. 2020; 294: 113493.
  26. Brown E, Gray R, Lo Monaco S, et al. The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research. Schizophr Res. 2020; 222: 79–87.
  27. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216–226.
  28. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18(1): 53–66.
  29. Muruganandam P, Neelamegam S, Menon V, et al. COVID-19 and Severe Mental Illness: Impact on patients and its relation with their awareness about COVID-19. Psychiatry Res. 2020; 291: 113265.
  30. SAMSHA- The Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. Aug 2019.
  31. Liu X, Lin H, Jiang H, et al. Clinical characteristics of hospitalised patients with schizophrenia who were suspected to have coronavirus disease (COVID-19) in Hubei Province, China. Gen Psychiatr. 2020; 33(2): e100222.
  32. Iancu I, Strous R, Poreh A, et al. Psychiatric inpatients' reactions to the SARS epidemic: an Israeli survey. Isr J Psychiatry Relat Sci. 2005; 42(4): 258–262.
  33. Ma J, Hua T, Zeng K, et al. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. Transl Psychiatry. 2020; 10(1): 411.
  34. Cowan HR. Is schizophrenia research relevant during the COVID-19 pandemic? Schizophr Res. 2020; 220: 271–272.
  35. Hansen D, Baandrup L, Hageman I. COVID-19 associeret tilbagefald af svær psykose. Ugeskrift for Læger. 2020; 182: V05200354.
  36. Kępińska AP, Iyegbe CO, Vernon AC, et al. Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Front Psychiatry. 2020; 11: 72.
  37. Khandaker GM, Zimbron J, Dalman C, et al. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012; 139(1-3): 161–168.
  38. Koponen H, Rantakallio P, Veijola J, et al. Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1): 9–13.
  39. Leask SJ, Done DJ, Crow TJ. Adult psychosis, common childhood infections and neurological soft signs in a national birth cohort. Br J Psychiatry. 2002; 181: 387–392.
  40. Dalman C, Allebeck P, Gunnell D, et al. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry. 2008; 165(1): 59–65.
  41. Watson CJ, Thomas RH, Solomon T, et al. COVID-19 and psychosis risk: Real or delusional concern? Neurosci Lett. 2021; 741: 135491.
  42. Lynch A, Bastiampillai T, Dhillon R. Can COVID-19-related anxiety trigger a relapse of schizophrenia? Aust N Z J Psychiatry. 2020 [Epub ahead of print]: 4867420954564.
  43. Sanchez-Alonso S, Ovejero S, Barrigon ML, et al. Psychotic relapse from COVID-19 quarantine, a case report. Psychiatry Res. 2020; 290: 113114.
  44. Starace F, Ferrara M. COVID-19 disease emergency operational instructions for Mental Health Departments issued by the Italian Society of Epidemiological Psychiatry. Epidemiol Psychiatr Sci. 2020; 29: e116.
  45. Guan I, Kirwan N, Beder M, et al. Adaptations and Innovations to Minimize Service Disruption for Patients with Severe Mental Illness during COVID-19: Perspectives and Reflections from an Assertive Community Psychiatry Program. Community Ment Health J. 2021; 57(1): 10–17.